Acadia Pharmaceuticals Inc (ACAD) · Oct 23, 2026 · Exec change

Acadia executive change: R&D chief exits, stays on as consultant

R&D transition — Consulting through December 31, 2026; replacement not yet named

Acadia’s executive change is now effective: its R&D chief leaves the employee role but remains a consultant while a replacement search continues.

Acadia is a commercial neuroscience and rare-disease company built around Nuplazid and Daybue, while trying to advance remlifanserin and other pipeline programs into later-stage development. Its R&D leadership is especially relevant because remlifanserin is the lead growth program and the company is moving from clinical readout toward Phase 3 execution.

The departure is now operational, not newly announced. Elizabeth Thompson no longer serves as an employee or Head of R&D as of October 23, but Acadia had already disclosed her planned retirement on April 30 and said she would remain involved through the transition. 〔0〕 The filing therefore confirms a scheduled change rather than introducing a surprise.

The consultant arrangement reduces near-term disruption but does not solve the leadership gap. Thompson intends to provide limited consulting services through December 31, while Acadia is still identifying her replacement. 〔1〕 That provides a short continuity bridge, but the company has not named the person who will own R&D beyond year-end.

Bottom line: This is a priced-in executive transition with a temporary continuity measure, not a change to Acadia’s clinical strategy or pipeline. It matters mainly because the replacement search remains unfinished as the company advances its next-stage development work.

What to watch next

Appointment of replacement Head of R&D

Original filing on SEC EDGAR

More Acadia Pharmaceuticals Inc news

Acadia executive change: R&D chief exits, stays on as consultant | ACAD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.